Clinical trials: RA - Rheumatoid Arthritis
Rheumatoid Arthritis
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
In this study, patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab).
- Trial name
- REFLECTIONS (NCT01526057)
- Testing
- PF-05280586, MabThera, Rituxan
- Where
- 84 sites in United States, Australia and 8 more
- Volunteers
- 220 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment
This open-label, single-arm study will evaluate the efficacy, safety and tolerability of subcutaneously administered tocilizumab in monotherapy and/or in combination with methotrexate and other non-biologic disease modifying…
- Trial name
- NCT02031471
- Testing
- tocilizumab
- Where
- 17 sites in Belgium, Luxembourg
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid, Arthritis, Psoriatic
A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)
This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
- Conditions
- Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing
- Trial name
- GO-NICE (NCT01313858)
- Testing
- Simponi®, Methotrexate
- Volunteers
- 1,613 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
This was a Phase II, randomized, open-label, multicenter study designed to evaluate the immune response to vaccines after administration of 1000 mg of rituximab in subjects with active rheumatoid arthritis (RA) who were receiving…
- Trial name
- SIERRA (NCT00282308)
- Testing
- Rituximab, Methotrexate, Methylprednisone
- Where
- 34 sites in United States
- Volunteers
- 103 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
This is a randomized double-blind comparative parallel group study of the efficacy and safety of tocilizumab biosimilar Complarate® and Actemra® in the treatment of patients with rheumatoid arthritis with moderate to high disease…
- Trial name
- NCT06475508
- Testing
- Complarate®, Actemra®
- Where
- 28 sites in Russia
- Volunteers
- 465 people
- Sponsor
- AO GENERIUM
Rheumatoid Arthritis
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
This six months non-interventional, observational, post-marketing, multi-center and local study will evaluate the differences in the use of corticosteroids between RA participants receiving TCZ or a TNF-inhibitor, in participants…
- Trial name
- NCT02679001
- Testing
- TNF inhibitor/TCZ
- Where
- 11 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer.
- Trial name
- NCT01643928
- Testing
- Rituximab-Pfizer (PF-05280586) x 3 courses, Rituximab-EU+ Rituximab-Pfizer x 2 Courses, Rituximab-US + Rituximab-Pfizer x 2 Courses
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects
This study is to evaluate the efficacy and safety of ASP015K monotherapy and to evaluate the dose-dependent response of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects given ASP015K for 12 weeks.
- Trial name
- NCT01649999
- Testing
- peficitinib
- Where
- 7 sites in Japan
- Volunteers
- 281 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs
This is a randomized, vehicle controlled, double-blind, repeat dose comparative study in patients with rheumatoid arthritis (RA) under management with DMARDs and with persistent disease activity.
- Trial name
- NCT04286789
- Testing
- Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oryn Therapeutics, LLC
Rheumatoid Arthritis
A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA
A key challenge in the management of patients with Rheumatoid Arthritis (RA) is the early identification of patients that are at risk of developing a severe and destructive disease.
- Trial name
- NCT01078597
- Where
- 4 sites in Ireland
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis
Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic inflammation in the synovial tissue. Rheumatoid arthritis will eventually result in the destruction of cartilage, bone and ligaments and joint…
- Trial name
- RA (NCT01547091)
- Testing
- Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs), Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs), UC-MSC+DMARDS
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Alliancells Bioscience Corporation Limited
Rheumatoid Arthritis (RA)
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis…
- Trial name
- NCT03660059
- Testing
- Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 385 people
- Sponsor
- Astellas Pharma China, Inc.
Rheumatoid Arthritis
Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.
This study will compare injection site pain levels between current Humira® formulation versus a new formulation of Humira in patients with Rheumatoid Arthritis (RA), who are either currently on a stable dose (minimum six…
- Trial name
- NCT01561313
- Testing
- Adalimumab
- Where
- 6 sites in Belgium, Czechia
- Volunteers
- 64 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
The purpose of the study is to evaluate the effectiveness of four dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding.
- Trial name
- OSKIRA-Asia-1 (NCT01569074)
- Testing
- Fostamatinib
- Where
- 34 sites in Hong Kong, Japan and 4 more
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
The purpose of this study is to establish proof of concept and identify the optimal efficacious dose for namilumab in RA in patients with an inadequate response to methotrexate (MTX-IR) and in patients with an inadequate response…
- Trial name
- NEXUS (NCT02379091)
- Testing
- Namilumab, Methotrexate, Folic/folinic acid
- Where
- 31 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 108 people
- Sponsor
- Takeda
Rheumatoid Arthritis
Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)
The purpose of this study is to compare the incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other…
- Trial name
- NCT01088360
- Volunteers
- 20,000 people
- Sponsor
- Bristol-Myers Squibb
Juvenile Rheumatoid Arthritis
Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese children with Polyarticular Juvenile Rheumatoid Arthritis
- Trial name
- NCT00690573
- Testing
- Adalimumab
- Where
- 12 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic…
- Trial name
- NCT06859294
- Testing
- LY3541860
- Where
- 20 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Osteoarthritis Shoulder, Rheumatoid Arthritis
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
The objective of this study is to collect and evaluate long-term clinical outcomes data in order to better understand the safety and performance of the Equinoxe Humeral Reconstruction Prosthesis in shoulder arthroplasty over…
- Conditions
- Osteoarthritis Shoulder, Rheumatoid Arthritis, Oncology
- Trial name
- HRP (NCT05615246)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Exactech
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)
This observational study will assess the efficacy and safety of MabThera/Rituxan (Rituximab) in patients with active rheumatoid arthritis who have had an inadequate response or are intolerant to anti-TNF therapy.
- Trial name
- NCT01196780
- Where
- Romania
- Volunteers
- 1,240 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.